CL2014002541A1 - Compuestos derivados de imidazol fusionado con heterociclos, como inhibidores de diacilglicerol aciltransferasa 2; composicion farmaceutica que los comprende, util para el tratamiento de diabetes tipo i y ii, enfermedad cardiaca coronaria, artritis, trombosis, alzheimer, entre otras enfermedades. - Google Patents

Compuestos derivados de imidazol fusionado con heterociclos, como inhibidores de diacilglicerol aciltransferasa 2; composicion farmaceutica que los comprende, util para el tratamiento de diabetes tipo i y ii, enfermedad cardiaca coronaria, artritis, trombosis, alzheimer, entre otras enfermedades.

Info

Publication number: CL2014002541A1
Authority: CL; Chile
Prior art keywords: thrombosis; alzheimer; arthritis; diabetes; inhibitors
Prior art date: 2012-04-06

Application number

CL2014002541A

Other languages

English (en)

Inventor

Jian Wang

Kay Ahn

Markus Boehm

Shawn Cabral

Philip A Carpino

Kentaro Futatsugi

David Hepworth

Daniel W Kung

Suvi Orr

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-04-06

Filing date

2014-09-25

Publication date

2015-01-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48428540&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002541(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-09-25 Application filed by Pfizer filed Critical Pfizer

2015-01-16 Publication of CL2014002541A1 publication Critical patent/CL2014002541A1/es

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Immunology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Gynecology & Obstetrics (AREA)
Gastroenterology & Hepatology (AREA)
Vascular Medicine (AREA)

CL2014002541A 2012-04-06 2014-09-25 Compuestos derivados de imidazol fusionado con heterociclos, como inhibidores de diacilglicerol aciltransferasa 2; composicion farmaceutica que los comprende, util para el tratamiento de diabetes tipo i y ii, enfermedad cardiaca coronaria, artritis, trombosis, alzheimer, entre otras enfermedades. CL2014002541A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201261621144P	2012-04-06	2012-04-06

Publications (1)

Publication Number	Publication Date
CL2014002541A1 true CL2014002541A1 (es)	2015-01-16

Family

ID=48428540

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014002541A CL2014002541A1 (es)	2012-04-06	2014-09-25	Compuestos derivados de imidazol fusionado con heterociclos, como inhibidores de diacilglicerol aciltransferasa 2; composicion farmaceutica que los comprende, util para el tratamiento de diabetes tipo i y ii, enfermedad cardiaca coronaria, artritis, trombosis, alzheimer, entre otras enfermedades.

Country Status (27)

Country	Link
US (1)	US9296745B2 (es)
EP (1)	EP2834238B1 (es)
JP (1)	JP2015515472A (es)
KR (1)	KR20140137404A (es)
CN (1)	CN104334557A (es)
AP (1)	AP2014007953A0 (es)
AU (1)	AU2013245353A1 (es)
CA (1)	CA2869587A1 (es)
CL (1)	CL2014002541A1 (es)
CO (1)	CO7160030A2 (es)
CR (1)	CR20140468A (es)
CU (1)	CU20140115A7 (es)
DO (1)	DOP2014000225A (es)
EA (1)	EA201400990A1 (es)
EC (1)	ECSP14021251A (es)
GT (1)	GT201400213A (es)
HK (1)	HK1206735A1 (es)
IL (1)	IL234928A0 (es)
MA (1)	MA37385B1 (es)
MD (1)	MD20140103A2 (es)
MX (1)	MX2014011373A (es)
NI (1)	NI201400120A (es)
PE (1)	PE20142164A1 (es)
PH (1)	PH12014502057A1 (es)
SG (1)	SG11201405477XA (es)
TN (1)	TN2014000419A1 (es)
WO (1)	WO2013150416A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9255154B2 (en)	2012-05-08	2016-02-09	Alderbio Holdings, Llc	Anti-PCSK9 antibodies and use thereof
AR098394A1 (es) *	2013-11-25	2016-05-26	Lilly Co Eli	Inhibidores de dgat2 (diacilglicerol o-aciltransferasa 2)
GEP20186864B (en)	2014-03-17	2018-06-25	Pfizer	Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
DK3239143T3 (da) *	2014-12-24	2023-04-11	Lg Chemical Ltd	Biarylderivat som gpr120-agonist
EP3298001B1 (en)	2015-05-20	2020-05-13	Eli Lilly and Company	Dgat2 inhibitors
PE20180800A1 (es) *	2015-07-10	2018-05-09	Ionis Pharmaceuticals Inc	Moduladores de diaciglicerol aciltransferasa 2 (dgat2)
US20190055212A1 (en) *	2016-02-16	2019-02-21	Stephen Gwaltney	Histone demethylase inhibitors
AR109179A1 (es)	2016-08-19	2018-11-07	Pfizer	Inhibidores de diacilglicerol aciltransferasa 2
KR20210118840A (ko)	2019-01-24	2021-10-01	다이이찌 산쿄 가부시키가이샤	치환기를 갖는 우레아 화합물
TWI771766B (zh)	2019-10-04	2022-07-21	美商輝瑞股份有限公司	二醯基甘油醯基轉移酶２抑制劑
JP2022058085A (ja)	2020-02-24	2022-04-11	ファイザー・インク	ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
CN111214449B (zh) *	2020-03-02	2021-09-07	广东彼迪药业有限公司	一种盐酸西替利嗪片剂及其制备方法
US11478533B2 (en)	2020-04-27	2022-10-25	Novo Nordisk A/S	Semaglutide for use in medicine
WO2021236401A1 (en)	2020-05-18	2021-11-25	Merck Sharp & Dohme Corp.	Novel diacylglyceride o-acyltransferase 2 inhibitors
TWI817191B (zh) *	2020-09-04	2023-10-01	南韓商Ｌｇ化學股份有限公司	新穎聯芳基衍生物及其作為針對二醯基甘油醯基轉移酶２之抑制劑之用途
US11976061B2 (en)	2020-10-08	2024-05-07	Merck Sharp & Dohme, LLC	Preparation of benzimidazolone derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors
WO2023026180A1 (en)	2021-08-26	2023-03-02	Pfizer Inc.	Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide
WO2023159154A1 (en) *	2022-02-18	2023-08-24	Bristol-Myers Squibb Company	Substituted imidazopyridinyl compounds useful as inhibitors of tlr9

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3065190D1 (en)	1979-11-05	1983-11-10	Beecham Group Plc	Enzyme derivatives, and their preparation
DK0580860T4 (da)	1991-04-16	2005-03-21	Nippon Shinyaku Co Ltd	Fremgangsmåde til fremstilling af en fast dispersion
US5612359A (en)	1994-08-26	1997-03-18	Bristol-Myers Squibb Company	Substituted biphenyl isoxazole sulfonamides
DE19504832A1 (de)	1995-02-14	1996-08-22	Basf Ag	Feste Wirkstoff-Zubereitungen
TW536540B (en)	1997-01-30	2003-06-11	Bristol Myers Squibb Co	Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
EP0901786B1 (en)	1997-08-11	2007-06-13	Pfizer Products Inc.	Solid pharmaceutical dispersions with enhanced bioavailability
TR200100149T2 (tr)	1998-07-06	2001-10-22	Bristol-Myers Squibb Company	Dual anjiyotensin endotelin alıcı antagonistleri olarak bifenil-sülfonamitler
MY125533A (en)	1999-12-06	2006-08-30	Bristol Myers Squibb Co	Heterocyclic dihydropyrimidine compounds
DE60219295T2 (de)	2001-02-28	2008-01-03	Merck & Co., Inc.	Acylierte piperidinderivate als melanocortin-4-rezeptoragonisten
US7064215B2 (en) *	2001-07-03	2006-06-20	Chiron Corporation	Indazole benzimidazole compounds
KR20040095239A (ko)	2002-02-27	2004-11-12	화이자 프로덕츠 인코포레이티드	Ａｃｃ 억제제
FR2852957B1 (fr) *	2003-03-31	2005-06-10	Sod Conseils Rech Applic	Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
AR044152A1 (es)	2003-05-09	2005-08-24	Bayer Corp	Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
WO2005116014A1 (en)	2004-05-12	2005-12-08	Pfizer Products Inc.	Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
JP4069159B2 (ja)	2004-05-25	2008-04-02	ファイザー・プロダクツ・インク	テトラアザベンゾ［ｅ］アズレン誘導体及びそれらのアナログ
PA8660701A1 (es)	2005-02-04	2006-09-22	Pfizer Prod Inc	Agonistas de pyy y sus usos
ES2274712B1 (es)	2005-10-06	2008-03-01	Laboratorios Almirall S.A.	Nuevos derivados imidazopiridina.
EP2010520B1 (en)	2006-04-20	2012-09-12	Pfizer Products Inc.	Heterobicyclic amides for the prevention and treatment of glucokinase-mediated diseases
ATE552262T1 (de)	2006-11-29	2012-04-15	Pfizer Prod Inc	Spiroketone als inhibitoren von acetyl-coa- carboxylase
AU2007336811A1 (en)	2006-12-21	2008-07-03	Plexxikon, Inc.	Compounds and methods for kinase modulation, and indications therefor
US20090036425A1 (en)	2007-08-02	2009-02-05	Pfizer Inc	Substituted bicyclolactam compounds
JP5435592B2 (ja)	2008-05-28	2014-03-05	ファイザー・インク	ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤
US20110009443A1 (en)	2008-05-28	2011-01-13	Kevin Daniel Freeman-Cook	Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors
US20110130365A1 (en)	2008-07-29	2011-06-02	Benbow John W	Fluorinated Heteroaryls
EP2334687B9 (en)	2008-08-28	2012-08-08	Pfizer Inc.	Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
TW201038580A (en)	2009-02-02	2010-11-01	Pfizer	4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
CN102388038B (zh)	2009-03-11	2014-04-23	辉瑞大药厂	用作葡糖激酶活化剂的苯并呋喃基衍生物
EP2406230A1 (en)	2009-03-11	2012-01-18	Pfizer Inc.	Substituted indazole amides and their use as glucokinase activators
EP2408780A2 (en)	2009-03-20	2012-01-25	Pfizer Inc.	3-oxa-7-azabicycloý3.3.1¨nonanes
AU2010243353B2 (en)	2009-04-30	2014-09-11	Astex Therapeutics Limited	Imidazole derivatives and their use as modulators of Cyclin dependent Kinases
JP2012526097A (ja)	2009-05-08	2012-10-25	ファイザー・インク	Ｇｐｒ１１９調節因子
WO2010128414A1 (en)	2009-05-08	2010-11-11	Pfizer Inc.	Gpr 119 modulators
BRPI1014636A2 (pt)	2009-06-05	2016-04-05	Pfizer	moduladores de gpr 119
WO2011005611A1 (en)	2009-07-09	2011-01-13	Merck Sharp & Dohme Corp.	Neuromedin u receptor agonists and uses thereof

2013
- 2013-03-26 CA CA2869587A patent/CA2869587A1/en not_active Abandoned
- 2013-03-26 MD MDA20140103A patent/MD20140103A2/ro not_active Application Discontinuation
- 2013-03-26 WO PCT/IB2013/052404 patent/WO2013150416A1/en active Application Filing
- 2013-03-26 KR KR20147027517A patent/KR20140137404A/ko not_active Application Discontinuation
- 2013-03-26 EA EA201400990A patent/EA201400990A1/ru unknown
- 2013-03-26 JP JP2015503965A patent/JP2015515472A/ja not_active Ceased
- 2013-03-26 MA MA37385A patent/MA37385B1/fr unknown
- 2013-03-26 CN CN201380029783.XA patent/CN104334557A/zh active Pending
- 2013-03-26 AU AU2013245353A patent/AU2013245353A1/en not_active Abandoned
- 2013-03-26 US US14/384,508 patent/US9296745B2/en active Active
- 2013-03-26 EP EP13722085.1A patent/EP2834238B1/en active Active
- 2013-03-26 SG SG11201405477XA patent/SG11201405477XA/en unknown
- 2013-03-26 AP AP2014007953A patent/AP2014007953A0/xx unknown
- 2013-03-26 MX MX2014011373A patent/MX2014011373A/es unknown
- 2013-03-26 PE PE2014001527A patent/PE20142164A1/es not_active Application Discontinuation
2014
- 2014-09-16 PH PH12014502057A patent/PH12014502057A1/en unknown
- 2014-09-25 CL CL2014002541A patent/CL2014002541A1/es unknown
- 2014-09-26 CU CU2014000115A patent/CU20140115A7/es unknown
- 2014-10-01 IL IL234928A patent/IL234928A0/en unknown
- 2014-10-02 EC ECIEPI201421251A patent/ECSP14021251A/es unknown
- 2014-10-02 TN TN2014000419A patent/TN2014000419A1/fr unknown
- 2014-10-03 NI NI201400120A patent/NI201400120A/es unknown
- 2014-10-06 DO DO2014000225A patent/DOP2014000225A/es unknown
- 2014-10-06 CR CR20140468A patent/CR20140468A/es unknown
- 2014-10-06 CO CO14221244A patent/CO7160030A2/es unknown
- 2014-10-06 GT GT201400213A patent/GT201400213A/es unknown
2015
- 2015-07-30 HK HK15107295.0A patent/HK1206735A1/xx unknown

Also Published As

Publication number	Publication date
SG11201405477XA (en)	2014-11-27
CO7160030A2 (es)	2015-01-15
NI201400120A (es)	2015-11-18
JP2015515472A (ja)	2015-05-28
MD20140103A2 (ro)	2015-01-31
IL234928A0 (en)	2014-12-31
MA201637385A2 (fr)	2016-03-31
HK1206735A1 (en)	2016-01-15
CR20140468A (es)	2014-11-17
TN2014000419A1 (fr)	2016-03-30
CA2869587A1 (en)	2013-10-10
KR20140137404A (ko)	2014-12-02
MA37385B1 (fr)	2019-09-30
EA201400990A1 (ru)	2015-01-30
EP2834238B1 (en)	2017-02-01
ECSP14021251A (es)	2015-09-30
GT201400213A (es)	2015-06-02
US9296745B2 (en)	2016-03-29
PE20142164A1 (es)	2014-12-27
MA37385A3 (fr)	2016-12-30
PH12014502057A1 (en)	2014-12-10
AP2014007953A0 (en)	2014-09-30
WO2013150416A1 (en)	2013-10-10
EP2834238A1 (en)	2015-02-11
CN104334557A (zh)	2015-02-04
MX2014011373A (es)	2014-10-14
US20150087585A1 (en)	2015-03-26
AU2013245353A1 (en)	2014-09-25
CU20140115A7 (es)	2014-11-27
DOP2014000225A (es)	2014-11-30

Publication	Publication Date	Title
CL2014002541A1 (es)	2015-01-16	Compuestos derivados de imidazol fusionado con heterociclos, como inhibidores de diacilglicerol aciltransferasa 2; composicion farmaceutica que los comprende, util para el tratamiento de diabetes tipo i y ii, enfermedad cardiaca coronaria, artritis, trombosis, alzheimer, entre otras enfermedades.
CL2014003388A1 (es)	2015-04-10	Compuestos derivados de triazolona, como inhibidores de mpges-1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, util para el tratamiento de inflamacion, asma, epoc, artritis, enfermedad de parkinson y enfermedades autoinmunes, entre otras enfermedades.
CU20170015A7 (es)	2017-06-05	Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il
DOP2016000094A (es)	2016-07-15	Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4.
CL2015001268A1 (es)	2015-07-10	Compuestos derivados de pirrolopirimidina, como inhibidores de quinasas; composicion farmaceutica que los comprende, util para el tratamiento de una enfermedad o condicion autoinmune tal como artritis reumatoide o lupus, y para el tratamiento de una enfermedad o condicion heteroinmune o inflamatoria.
CL2014003277A1 (es)	2015-07-10	Compuestos derivados heterociclicos sustituidos por carboxamida o sulfonamida, como moduladores para el receptor nuclear huerfano rorgama; composicion farmaceutica que los comprende, util para el tratamiento de artritis reumatoide, lupus eritematoso, psoriasis, esclerosis multiple, diabetes tipo 1, colitis ulcerosa, enfermedad pulmonar obstructiva cronica, entre otras.
CL2014002983A1 (es)	2015-04-17	Compuestos derivados de 1h-pirazolo[3,4-b]piridina, como inhibidores de una o mas proteinas en la ruta de wnt; composicion farmaceutica que los comprende, util para el tratamiento de cancer, retinopatia diabetica, fibrosis pulmonar, artritis reumatoide, enfermedad de alzheimer, entre otras.
BR112017024917A2 (pt)	2018-07-31	síntese de compostos heterocíclicos
BR112017003975A2 (pt)	2018-01-30	composição de conjugado de ligante e fármaco, e, composto ligador de fármaco.
UY36056A (es)	2015-10-30	“compuestos de heteroarilo o arilo bicíclicos fusionados “.
CL2015000945A1 (es)	2015-08-28	Compuestos derivados de quinolina, como moduladores del receptor nuclear ror-gammat; composicion farmaceutica que los comprende; su proceso de elaboracion, util para el tratamiento de una enfermedad inflamatoria tal como artritis reumatoide, soriasis, epoc, enfermedad de crohn, esclerosis multiple, lupus eritematoso sistemico y colitis ulcerativa.
DOP2016000144A (es)	2016-08-15	Moduladores de tetrahidropiridopirazinas de gpr6
CL2013003472A1 (es)	2014-08-18	Compuestos derivados de halogenoalquil-1,3-oxazinas sustituidas, inhibidores de la bace1 y/o bace2; procedimiento de obtencion; composicion farmaceutica que los comprende; su uso en el tratamiento y/o profilaxis de enfermedades tales como diabetes, alzheimer, als, enfermedades autoinmunes inflamatorias, cancer, entre otras.
CO2018004473A2 (es)	2018-09-20	Compuestos agonistas de ppar y composiciones farmaceuticas
UY34657A (es)	2013-10-31	?derivados macrocíclicos para el tratamiento de enfermedades?.
CL2015000080A1 (es)	2015-04-10	Compuestos derivados de purinas macrociclicas y sus sales; composicion farmaceutica que los comprende, util para el tratamiento de un trastorno en el que interviene la modulacion de tlr7, tales como infecciones viricas, trastornos inmunitarios o inflamatorios.
BR112013032717A2 (pt)	2017-01-24	coagonistas do receptor de glucagon/glp-1
BR112015023001A2 (pt)	2017-11-14	composição de salto de exon para tratamento de distrofia muscular
CL2014000746A1 (es)	2014-10-03	Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer.
CL2015001279A1 (es)	2015-06-26	Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras.
CL2010001637A1 (es)	2011-07-15	Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras.
CL2015000615A1 (es)	2015-08-28	Compuestos derivados de 4-amino-quinolinas, inhibidores de rip2 cinasa; composicion farmaceutica que los comprende; uso para el tratamiento de enfermedades tales como enfermedad de crohn, colitis ulcerativa o sindrome de blau.
EA201600589A1 (ru)	2017-03-31	Ингибиторы диацилглицеринацилтрансферазы 2 для применения в лечении метаболических и связанных с метаболизмом расстройств
CL2014002661A1 (es)	2014-12-26	Compuestos derivados de tienopirimidina o sus sales, como inhibidores de la alk quinasa; su proceso de preparacion; composicion farmaceutica que los comprende, util para el tratamiento del cancer.
CL2015000717A1 (es)	2015-06-19	Compuestos derivados de piridinonas biciclicas y sus sales; composicion farmaceutica que los comprende; y su uso para el tratamiento de la neurodegeneracion y trastornos psiquiatricos, que incluyen enfermedad de alzheimer o enfermedad de niemann-pick tipo c.